Duramed to acquire FEI Women's Health, ParaGard IUD

By Jennifer Chiou

New York, Oct. 18 - Duramed Pharmaceuticals, Inc. announced it will acquire FEI Women's Health, LLC for $281.5 million.

The transaction will expand the company's presence into the non-hormone contraceptive product marketplace as FEI owns the new drug application for the ParaGard T380A intrauterine copper contraceptive IUD for continuous pregnancy prevention for up to 10 years. In 2004, ParaGard sales were about $48 million.

The transaction is expected to close by the end of the year.

"With this transaction, we will expand our commitment to contraception beyond oral contraceptive products into a new arena for the company," Barr chairman and chief executive officer Bruce L. Downey said in a news release.

"IUDs represent an under-utilized contraceptive option for women in the United States, and we believe that we are well positioned to grow this category through consumer and professional education and marketing."

Based in Woodcliff Lake, N.J., Barr Pharmaceuticals, Inc. is a holding company whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, develop and market generic and proprietary pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.